| Association of reduced-intensity conditioning regimens with overall survival among patients with non-Hodgkin lymphoma undergoing allogeneic transplant N Ghosh, S Ahmed, KW Ahn, M Khanal, C Litovich, M Aljurf, VU Bacher, ... JAMA oncology 6 (7), 1011-1018, 2020 | 43 | 2020 |
| Exploring patterns of demand in bike sharing systems via replicated point process models D Gervini, M Khanal Journal of the Royal Statistical Society Series C: Applied Statistics 68 (3 …, 2019 | 26 | 2019 |
| Impact of reduced-intensity conditioning regimens on outcomes in diffuse large B cell lymphoma undergoing allogeneic transplantation N Epperla, KW Ahn, M Khanal, C Litovich, S Ahmed, N Ghosh, TS Fenske, ... Transplantation and cellular therapy 27 (1), 58-66, 2021 | 21 | 2021 |
| Impact of type of reduced‐intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma S Ahmed, N Ghosh, KW Ahn, M Khanal, C Litovich, A Mussetti, S Chhabra, ... British journal of haematology 190 (4), 573-582, 2020 | 18 | 2020 |
| Noninfectious pulmonary toxicity after allogeneic hematopoietic cell transplantation SS Patel, KW Ahn, M Khanal, C Bupp, M Allbee-Johnson, NS Majhail, ... Transplantation and cellular therapy 28 (6), 310-320, 2022 | 13 | 2022 |
| Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the … TA Eyre, LM Hess, T Sugihara, D He, M Khanal, JM Pagel, RA Walgren, ... Leukemia & Lymphoma 64 (5), 1005-1016, 2023 | 10 | 2023 |
| Higher total body irradiation dose intensity in fludarabine/TBI-based reduced-intensity conditioning regimen is associated with inferior survival in non-Hodgkin lymphoma … M Hamadani, M Khanal, KW Ahn, C Litovich, VA Chow, A Eghtedar, ... Biology of Blood and Marrow Transplantation 26 (6), 1099-1105, 2020 | 8 | 2020 |
| adjSURVCI: Parameter and Adjusted Probability Estimation of Right-Censored Data M Khanal, KW Ahn https://CRAN.R-project.org/package=adjSURVCI, 2021 | 3 | 2021 |
| Comparison of reduced-intensity conditioning (RIC) regimens for allogeneic hematopoietic cell transplantation (alloHCT) in non-Hodgkin lymphomas (NHL)-a Center for … N Ghosh, S Ahmed, C Litovich, KW Ahn, M Khanal, MA Kharfan-Dabaja, ... Blood 134, 319, 2019 | 3 | 2019 |
| Adjusted curves for clustered survival and competing risks data M Khanal, S Kim, KW Ahn Communications in Statistics-Simulation and Computation, 1-24, 2023 | 2 | 2023 |
| Competing risks regression for clustered data with covariate-dependent censoring M Khanal, S Kim, X Fang, K Woo Ahn Communications in Statistics-Theory and Methods, 1-19, 2024 | 1 | 2024 |
| Higher Total Body Irradiation (TBI) Dose-Intensity in Fludarabine (Flu)/TBI-Based Reduced-Intensity Conditioning (RIC) Regimen Is Associated with Inferior Survival in Non … M Hamadani, C Litovich, M Khanal, MA Kharfan-Dabaja, KW Ahn Biology of Blood and Marrow Transplantation 26 (3), S21-S22, 2020 | 1 | 2020 |
| Matching Adjusted Indirect Comparison (MAIC) of Selpercatinib vs Cabozantinib in RET Mutation-Positive Advanced Medullary Thyroid Cancer (MTC) MH Jen, U Kiiskinen, M Khanal, Y Han, L Hess, W Tian, A Vickers VALUE IN HEALTH 26 (12), S18-S18, 2023 | | 2023 |
| CO21 Matching Adjusted Indirect Comparison (MAIC) of Selpercatinib Vs Cabozantinib in RET Mutation-Positive Advanced Medullary Thyroid Cancer (MTC) MH Jen, U Kiiskinen, M Khanal, Y Han, L Hess, W Tian, A Vickers Value in Health 26 (12), S18, 2023 | | 2023 |
| Real-World Use and Outcomes of Therapies, Including Venetoclax-Based Treatments, after Discontinuation of a Covalent BTK Inhibitor in Patients with Chronic Lymphocytic Leukemia … N Jain, TA Eyre, K Winfree, NR Bhandari, M Khanal, T Sugihara, P Abada, ... Blood 142, 5152, 2023 | | 2023 |
| 197P Treatment patterns and clinical outcomes of patients with unresectable advanced or metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA) in China: A … Y Zhang, J Zhang, X Xie, W Pan, G Wang, Q Dong, N Zhang, J Dong, ... Annals of Oncology 34, S1551, 2023 | | 2023 |
| 669P Patient-reported outcomes with selpercatinib in patients with RET-driven cancers in the phase I/II LIBRETTO-001 trial H Kang, LE Raez, Y Ohe, M Khanal, K Wang, Y Han, S Szymczak, ... Annals of Oncology 34, S470-S471, 2023 | | 2023 |
| CO114 Real-World Experience Among Patients with Mantle Cell Lymphoma after Covalent Bruton Tyrosine Kinase Inhibitor Use in the United States: A Retrospective Electronic Health … L Hess, M Khanal, T Sugihara, K Winfree, H Konig, PB Abada, B Goebel, ... Value in Health 26 (6), S36, 2023 | | 2023 |
| Semiparametric Regression Models for Clustered Right-Censored Data Under Clinical Trials and Observational Studies M Khanal The Medical College of Wisconsin, 2022 | | 2022 |
| Non-Infectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation (HCT): A Center for International Blood and Marrow Transplant Research (CIBMTR) Study SS Patel, KW Ahn, M Khanal, C Fretham, C Ustun, BK Hamilton, ... Blood 136, 7-8, 2020 | | 2020 |
